Publicaciones en las que colabora con JOSÉ JAVIER FERNÁNDEZ RUIZ (61)

2017

  1. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

    PLoS ONE, Vol. 12, Núm. 4

  2. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

    Methods in Enzymology (Academic Press Inc.), pp. 175-198

2016

  1. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

    Neuroscience, Vol. 339, pp. 191-209

2014

  1. Cannabinoids and the brain: New hopes for new therapies

    Cannabinoids (John Wiley and Sons Ltd), pp. 175-218

  2. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

    British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489

  3. Combining rimonabant and fentanyl in a single entity: Preparation and pharmacological results

    Drug Design, Development and Therapy, Vol. 8, pp. 263-277

  4. Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias

    Pathobiology, Vol. 81, Núm. 3, pp. 149-159

2013

  1. Description of a bivalent cannabinoid ligand with hypophagic properties

    Archiv der Pharmazie, Vol. 346, Núm. 3, pp. 171-179

  2. Design and synthesis of novel cannabinoid ligands based on a 1,2,3-triazole scaffold

    Letters in Drug Design and Discovery, Vol. 10, Núm. 2, pp. 169-172

  3. Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21

    Bioorganic and Medicinal Chemistry, Vol. 21, Núm. 7, pp. 1708-1716

2012

  1. Chromenopyrazoles: Non-psychoactive and Selective CB 1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

    ChemMedChem, Vol. 7, Núm. 3, pp. 452-463

2010

  1. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders

    CNS Neuroscience and Therapeutics, Vol. 16, Núm. 3

  2. The endocannabinoid system as a target for the treatment of neuronal damage

    Expert Opinion on Therapeutic Targets, Vol. 14, Núm. 4, pp. 387-404

2009

  1. Cannabinoids, multiple sclerosis and neuroprotection

    Expert Review of Clinical Pharmacology, Vol. 2, Núm. 6, pp. 645-660

2008

  1. Cannabinoid signaling system: does it play a function in cell proliferation and migration, neuritic elongation and guidance and synaptogenesis during brain ontogenesis?

    Cell adhesion & migration, Vol. 2, Núm. 4, pp. 246-248

  2. Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance

    Neuroscience, Vol. 153, Núm. 3, pp. 687-699

2007

  1. The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain

    Brain Research, Vol. 1145, Núm. 1, pp. 48-55

2005

  1. Therapeutic potential of the endocannabinoid system in the brain

    Mini-Reviews in Medicinal Chemistry, Vol. 5, Núm. 7, pp. 609-617

2004

  1. Behavioral and molecular changes elicited by acute administration of SR141716 to Δ 9 -tetrahydrocannabinol-tolerant rats: An experimental model of cannabinoid abstinence

    Drug and Alcohol Dependence, Vol. 74, Núm. 2, pp. 159-170

  2. Cannabinoids and gene expression during brain development

    Neurotoxicity Research, Vol. 6, Núm. 5, pp. 389-401